TNF and COVID-19–associated multisystem inflammatory syndrome in children: In refractory cases of both KD and MIS-C, additional therapy with a monoclonal antibody against TNF-α (infliximab), monoclonal antibodies to the IL-6 receptor (tocilizumab), IL-1 receptor antagonist (anakinra), and plasma exchange have all been used (37, 57–59).